The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2019 | Are hypomethylating agents useful in preventing relapse in AML and MDS?
Marcos de Lima, MD, University Hospitals Cleveland Medical Center, Cleveland, OH, discusses hypomethylating agents and their utility in preventing relapse in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
